Jeep Recalls 63,000 Cherokee Vehicles Due to Damaged Powertrains: NHTSA

More than 1,000 warranty claims have been made regarding Jeep Cherokee powertrains with damaged power transfer units.

Federal highway safety officials have announced a recall of 63,082 Jeep Cherokee vehicles due to a potential defect in the power transfer unit (PTU), which may result in loss of driving power and impaired parking functions.

The PTU is found in the powertrain of certain all-wheel drive and four-wheel drive vehicles. It allows the engine’s power to be split between the front and rear axles, enabling power to be automatically shifted depending on different traction requirements.

The U.S. National Highway Traffic Safety Administration (NHTSA) announced the Jeep Cherokee recall on January 21, warning that some 2017 through 2019 model year vehicles have PTU input shaft snap rings that may not have been properly installed, which could lead to significant damage within the engine, resulting in transmission failures and problems with driving or parking the vehicle.

Officials are warning that the defect can damage the PTU, causing transmission failure, loss of driving power or parking issues, which could increase the risk of auto accidents, rollaway incidents and injuries.

Do You Know About...

Childhood Diabetes Lawsuits Against Junk Food Industry

Lawyers are now pursuing financial compensation for families of children diagnosed with Type II diabetes, fatty liver disease and other chronic illnesses caused by addictive and harmful substances in ultra-processed foods.

Learn More

While FCA US LLC is not aware of any accidents or injuries related to the defect, the automaker has received 1,064 warranty claims, 55 service records, 43 field reports and 14 customer assistance records related to the issue.

FCA US LLC first became aware of the issue on June 4, 2020, after identifying multiple reports of Jeep Cherokee vehicles with reported PTU part failures. The company began investigating the issue in March 2023.

After further investigation, the company decided to conduct a voluntary safety recall on January 9, impacting 2017 through 2019 Jeep Cherokee vehicles.

Drivers are being advised to watch for a “Service 4WD” message, unusual noise, vibration or changes in driving quality, as these may indicate PTU damage.

Although the manufacturer has not yet announced an official repair, FCA plans to start sending recall notification letters to customers on February 13, 2025.

FCA’s number for this recall is 01C. Customers may contact FCA customer service at 1-800-853-1403, or the company’s contact for this recall, Emily C. Smith, via email at emily.c.smith@dot.gov.

Owners with any additional questions may also contact the National Highway Traffic Safety Administration Vehicle Safety Hotline at 1-888-327-4236 (TTY 1-800-424-9153), or go to www.nhtsa.gov.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Court Asked To Establish Valsartan Settlement Fund and Appoint Administrator
Court Asked To Establish Valsartan Settlement Fund and Appoint Administrator (Posted today)

The judge presiding over the federal Valsartan lawsuits has been asked to approve the creation of a qualified settlement fund, as well as appoint an administrator and custodian for funds that will be paid to former users of the recalled hypertension drugs who have developed cancer.

Depo-Provera Class Action Lawsuit Seeks Medical Monitoring Due to Brain Tumor Risks
Depo-Provera Class Action Lawsuit Seeks Medical Monitoring Due to Brain Tumor Risks (Posted 2 days ago)

Pfizer and other manufacturers of the Depo-Provera birth control shot have been included in a class action lawsuit seeking medical monitoring for women who received the injections, due to the increased risk of brain tumors.